- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Vor Bio to present phase 3 data on telitacicept for myasthenia gravis | 1 | Investing.com | ||
| Mi | Vor Biopharma: Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM | 2 | GlobeNewswire (USA) | ||
| Mi | Vor Biopharma Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| Fr | Vor Biopharma: Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum | 1 | GlobeNewswire (USA) | ||
| 27.08. | Vor Bio's Investigational Drug Scores Phase 3 Win In Autoimmune Kidney Disease Trial | 4 | Benzinga.com | ||
| 27.08. | Wechsel im Verwaltungsrat von Vor Biopharma: Drei Rücktritte und eine Neubesetzung | 4 | Investing.com Deutsch | ||
| 27.08. | Vor Bio, RemeGen late-stage trial of telitacicept in IgA nephropathy meets primary goal | 2 | Seeking Alpha | ||
| 27.08. | Vor Biopharma stock rises after collaborator's IgAN drug hits endpoint | 2 | Investing.com | ||
| VOR BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 27.08. | Vor Biopharma: Aktionäre genehmigen Änderungen am Aktienplan und Aktienzusammenlegung | 3 | Investing.com Deutsch | ||
| 27.08. | Telitacicept von Vor Bio erreicht primären Endpunkt in Studie zu IgA-Nephropathie | 2 | Investing.com Deutsch | ||
| 27.08. | Vor Biopharma Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.08. | Vor Bio's telitacicept meets primary endpoint in IgA nephropathy trial | 2 | Investing.com | ||
| 18.08. | Vor Biopharma: Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 170 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, between August... ► Artikel lesen | |
| 13.08. | Vor Bio Rallies On Strong Data For Autoimmune Drug Candidate | 2 | Benzinga.com | ||
| 13.08. | Vor Bio: RemeGen Achieves Primary Endpoint In Phase 3 Study In China Evaluating Telitacicept | 3 | RTTNews | ||
| 13.08. | Vor Biopharma: Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor | 234 | GlobeNewswire (Europe) | Phase 3 results position telitacicept as potential best-in-disease profile in primary Sjögren's disease Telitacicept demonstrated a favorable safety profile Vor evaluating timing of global Phase 3... ► Artikel lesen | |
| 12.08. | Vor Biopharma Inc. - 10-Q, Quarterly Report | 10 | SEC Filings | ||
| 07.08. | Vor Bio hires commercial chief, reuniting ex-Sarepta colleagues in freshly rebuilt C-suite | 2 | FiercePharma | ||
| 04.08. | Vor Biopharma: Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer | 197 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment... ► Artikel lesen | |
| 22.07. | Vor Biopharma Inc. - 8-K, Current Report | 4 | SEC Filings |
1 2 3 4 Weiter >>
74 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EDITAS MEDICINE | 2,481 | +7,64 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| SOL GLOBAL INVESTMENTS | 0,033 | -3,79 % | SOL Global Investments Corp.: SOL Global Provides Digital Assets Update | Toronto, Ontario--(Newsfile Corp. - September 9, 2025) - SOL Global Investments Corp. (CSE: SOL) (OTCID: SOLCF) (FSE: 9SB) ("SOL Global" or the "Company") is pleased to provide an update regarding... ► Artikel lesen | |
| FATE THERAPEUTICS | 0,849 | +5,49 % | Fate Therapeutics, Inc.: Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent... ► Artikel lesen | |
| TRINITY BIOTECH | 1,210 | +0,83 % | Trinity Biotech plc: Trinity Biotech Regains Compliance with Nasdaq Listing Requirements | DUBLIN, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq Global Select: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 18,820 | +4,27 % | Cathie Wood's ARK ETF adjusts holdings, ARCT and TEM in focus | ||
| OVID THERAPEUTICS | 1,020 | +4,62 % | Ovid Therapeutics Inc. - 8-K, Current Report | ||
| EQUILLIUM | 1,308 | +0,62 % | Equillium, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| 4D MOLECULAR THERAPEUTICS | 7,090 | +6,46 % | 4D Molecular Therapeutics, Inc.: 4DMT Announces New Employment Inducement Grants | EMERYVILLE, Calif., Sept. 12, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted... ► Artikel lesen | |
| REGENCELL BIOSCIENCE | 15,085 | -2,30 % | Regencell Bioscience Holdings Limited Announces Forward Stock Split | HONG KONG, June 2, 2025 - Regencell Bioscience Holdings Limited (Nasdaq: RGC) (the "Company"), today announced that its board of directors approved a 38-for-one forward stock split to be paid in the... ► Artikel lesen | |
| GENERATION BIO | 5,870 | 0,00 % | Generation Bio Co.: Generation Bio Announces 1-for-10 Reverse Stock Split | CAMBRIDGE, Mass., July 18, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases... ► Artikel lesen | |
| CABALETTA BIO | 2,145 | +11,43 % | Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update | - Registrational cohort enrollment in RESET-Myositis trial on track to start in 2H25 with anticipated 2027 BLA submission for rese-cel in myositis - - Five disease-specific cohorts fully enrolled... ► Artikel lesen | |
| LONGEVERON | 0,760 | +1,16 % | Longeveron Announces Key Leadership Updates | Than Powell, Chief Business Officer and head of business development, appointed Interim CEODr. Joshua Hare, co-founder and chief science officer, appointed Executive Chairman of the Board of DirectorsWa'el... ► Artikel lesen | |
| PROKIDNEY | 2,630 | +4,16 % | ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates | FDA confirmed at a July 2025 Type B meeting and in the subsequent meeting minutes that eGFR slope is an acceptable surrogate endpoint for accelerated approval of rilparencel in patients with type... ► Artikel lesen | |
| ATHIRA PHARMA | - | - | Athira Pharma, Inc.: Athira Pharma Announces Reverse Stock Split | BOTHELL, Wash., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. ("Athira" or "Company") (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore... ► Artikel lesen | |
| BOLT PROJECTS | 3,620 | -0,28 % | Bolt Projects Holdings, Inc. - 8-K, Current Report |
VOR BIOPHARMA INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,055 (-3,61 %) liegt der Kurs bei 1,470 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VOR BIOPHARMA INC finden Sie auf Wallstreet Online.